Last $7.86 USD
Change Today -0.10 / -1.26%
Volume 51.2K
As of 1:46 PM 03/3/15 All times are local (Market data is delayed by at least 15 minutes).

derma sciences inc (DSCI) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/4/14 - $15.01
52 Week Low
03/2/15 - $7.72
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for DERMA SCIENCES INC (DSCI)

Related News

No related news articles were found.

derma sciences inc (DSCI) Related Businessweek News

No Related Businessweek News Found

derma sciences inc (DSCI) Details

Derma Sciences, Inc. operates as a tissue regeneration company in the wound care market. It operates in three segments: Advanced Wound Care, Traditional Wound Care, and Pharmaceutical Wound Care. The company offers Medihoney dressings for managing non-chronic and hard-to-heal wounds, such as chronic ulcers, burns, and post-operative wounds; TCC-EZ total contact cast system for patients with diabetic foot ulcers; AMNIOEXCEL for tissue repair and regeneration; and AMNIOMATRIX, which is used as a wound covering in the treatment of localized tissue defects. It also provides Xtrasorb dressings that convert fluid within the dressings to a gel and lock the exudates into the dressings; Bioguard dressings for prophylactic use in the prevention of hospital or community acquired infections through wound sites; ALGICELL AG antimicrobial dressings; and occlusive dressings, such as hydrocolloids, foams, hydrogels, alginates, additional silver antimicrobial dressings, cleansers, and DERMAGRAN products. In addition, the company offers gauze sponges and bandages, non-adherent impregnated dressings, retention devices, paste bandages, and other compression devices; adhesive bandages and related first aid products; wound closure strips, nasal tube fasteners, and catheter fasteners; and general purpose and specialized skin care products. Further, it develops DSC127, an angiotensin analog that is in Phase III clinical trials for the treatment of diabetic foot ulcers and preclinical testing for scar reduction. The company sells its products to various health care providers, such as wound care centers, extended care facilities, acute care facilities, home health care agencies, physicians’ offices, nursing homes, hospitals, and clinics through direct sales and manufacturers’ representatives, independent distributors, and retail channels primarily in the United States, Canada, and the United Kingdom. Derma Sciences, Inc. was founded in 1984 and is headquartered in Princeton, New Jersey.

258 Employees
Last Reported Date: 03/13/14
Founded in 1984

derma sciences inc (DSCI) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $450.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $260.0K
Executive Vice President of Operations and Ge...
Total Annual Compensation: $252.4K
Group President of Advanced Wound Care and Ph...
Total Annual Compensation: $280.0K
Group President of Traditional Wound Care and...
Total Annual Compensation: $240.0K
Compensation as of Fiscal Year 2013.

derma sciences inc (DSCI) Key Developments

Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement

Derma Sciences Inc. announced that AMNIOEXCEL® and AMNIOMATRIX®, amniotic allografts derived from placental tissues, have been added to the Premier Inc. Regenerative Skin Grafting contract portfolio. The announcement increases the opportunity for the AMNIOEXCEL® and AMNIOMATRIX® product lines, which continue to be adopted by clinicians in many health care facilities, including Veterans Administration and Military Hospitals, to be used in patient care. This partnership with Premier Inc. is an important milestone for its Amniotic Allograft product line as it continues to expand its presence as a leader in the tissue regeneration market.

Derma Sciences Inc. Announces Sales Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Sales Guidance for the Full Year of 2015

Derma Sciences Inc. announced sales results for the fourth quarter and full year ended December 31, 2014. For the year 2014, the company reported preliminary net sales of $83.7 million. For the fourth quarter of 2014, the company reported preliminary net sales were a record $22.9 million, of which $11.5 million were AWC, representing growth of 22% on a yearover year and sequential basis and $11.4 million were TWC, representing a 1% increase on a yearoveryear basis and 7% sequentially. The company also provided sales guidance for the full year of 2015. For the year ended December 31, 2014, the company expected 2015 net sales to be approximately $88.1 million, representing growth of 5% compared with preliminary 2014 net sales of $83.7 million. Net sales of advanced wound care (AWC) products are expected to be a record $43.8 million for the year, representing growth of 15% compared, with preliminary 2014 AWC net sales of $38.1 million. Net sales of traditional wound care (TWC) products are expected to be $44.3 million, representing a decline of 3% compared with preliminary 2014 TWC net sale of $45.6 million. TWC sales reflect the loss of a significant customer in 2015 due to industry consolidation.

Derma Sciences Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-03-2014 03:00 PM

Derma Sciences Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-03-2014 03:00 PM. Venue: The New York Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: Edward Joseph Quilty, Chairman, Chief Executive Officer and President.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DSCI:US $7.86 USD -0.10

DSCI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alliqua BioMedical Inc $5.48 USD -0.08
BioLargo Inc $0.38 USD -0.027
Integra LifeSciences Holdings Corp $60.58 USD -0.66
SANUWAVE Health Inc $0.18 USD -0.01
Smith & Nephew PLC 1,131 GBp -68.00
View Industry Companies

Industry Analysis


Industry Average

Valuation DSCI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.5x
Price/Book 1.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DERMA SCIENCES INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at